Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xolair in Peanut Allergy
NCT00086606Phase 2Terminated
- Sponsor
- Genentech
- Start
- Jun 2004
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of omalizumab in peanut allergy, sponsored by Genentech. Started Jun 2004; status: terminated.
02
Drugs
omalizumab
03
Conditions
peanut allergy
Beyond the preview
Go deeper on NCT00086606.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00086606.